The resistance mechanisms of proteasome inhibitor bortezomib

Biomarker Research

Volumn 1, Issue 1, 2013, Pages

  Lü, Shuqing ^a   Wang, Jianmin ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Bortezomib; Drug resistance; Mechanism; Proteasome inhibitor; PSMB5

Indexed keywords

2 METHOXYESTRADIOL; ARSENIC TRIOXIDE; BORTEZOMIB; CARFILZOMIB; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; OPROZOMIB; SOMATOMEDIN C; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR;

AMINO ACID SUBSTITUTION; CELL STRESS; CELL SURVIVAL; DRUG EFFICACY; ENDOPLASMIC RETICULUM STRESS; GENE; GENE SILENCING; HUMAN; HYDROGEN BOND; MICROARRAY ANALYSIS; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OPEN STUDY; PHASE 2 CLINICAL TRIAL (TOPIC); POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN STRUCTURE; PSMB5 GENE; REVIEW; UBIQUITINATION; UPREGULATION;

EID: 84897437312     PISSN: None     EISSN: 20507771     Source Type: Journal    
DOI: 10.1186/2050-7771-1-13     Document Type: Review

References (56)

1. Voges D, Zwickl P, Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Ann Rev Biochem 1999, 68:1015-1068. 10.1146/annurev.biochem.68.1.1015, 10872471.
2. Daniel KG, Kuhn DJ, Kazi A, Dou QP. Anti-angiogenic and anti-tumor properties of proteasome inhibitors. Curr Cancer Drug Targets 2005, 5:529-541. 10.2174/156800905774574075, 16305349.
3. Kisselev AF, Akopian TN, Castillo V, Goldberg AL. Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown. Mol Cell 1999, 4:395-402. 10.1016/S1097-2765(00)80341-X, 10518220.
4. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005, 23:630-639.
5. Rivett AJ. The multicatalytic proteinase. Multiple proteolytic activities. J Biol Chem 1989, 264:12215-12219.
6. Löwe J, Stock D, Jap B, Zwickl P, Baumeister W, Huber R. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science 1995, 268:533-539. 10.1126/science.7725097, 7725097.
7. Chen P, Hochstrasser M. Autocatalytic subunit processing couples active site formation in the 20S proteasome to completion of assembly. Cell 1996, 86:961-972. 10.1016/S0092-8674(00)80171-3, 8808631.
8. Murata S, Yashiroda H, Tanaka K. Molecular mechanisms of proteasome assembly. Nat Rev Mol Cell Biol 2009, 10:104-115. 10.1038/nrm2630, 19165213.
9. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001, 61:3071-3076.
10. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004, 5:417-421. 10.1016/S1535-6108(04)00120-5, 15144949.
11. Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, Newberry KJ, Sun L, Young KH, Champlin R, Kwak L, Feng L, Badillo M, Bejarano M, Hartig K, Chen W, Chen Y, Byrne C, Bell N, Zeldis J, Romaguera J. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348:2609-2617. 10.1056/NEJMoa030288, 12826635.
12. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC. Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators Bortezomib or high-dose dexamethazone for relapsed multiple myeloma. N Engl J Med 2005, 352:2487-2498. 10.1056/NEJMoa043445, 15958804, Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators.
13. Goy A, Younes A, McLaughlin P. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005, 23:667-675. 10.1200/JCO.2005.03.108, 15613697.
14. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 2004, 10:3371-3376. 10.1158/1078-0432.CCR-03-0508, 15161691.
15. Horton TM, Gannavarapu A, Blaney SM, D'Argenio DZ, Plon SE, Berg SL. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol 2006, 58:13-23. 10.1007/s00280-005-0135-z, 16292537.
16. Lü S, Yang J, Song X, Gong S, Zhou H, Guo L, Song N, Bao X, Chen P, Wang J. Point mutation of the PSMB5 gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line. J Pharmacol Exp Ther 2008, 326:423-431. 10.1124/jpet.108.138131, 18502982.
17. Lü S, Yang J, Chen Z, Gong S, Zhou H, Xu X, Wang J. Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line. Exp Hematol 2009, 37:831-837. 10.1016/j.exphem.2009.04.001, 19426847.
18. Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, Scheffer GL, Debipersad K, Vojtekova K, Lemos C, van der Heijden JW, Ylstra B, Peters GJ, Kaspers GL, Dijkmans BA, Scheper RJ, Jansen G. Molecular basis of bortezomib resistance: proteasome subunit beta 5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 2008, 112:2489-2499. 10.1182/blood-2007-08-104950, 18565852.
19. Franke NE, Niewerth D, Assaraf YG, van Meerloo J, Vojtekova K, van Zantwijk CH, Zweegman S, Chan ET, Kirk CJ, Geerke DP, Schimmer AD, Kaspers GJ, Jansen G, Cloos J. Impaired bortezomib binding to mutant b5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells. Leukemia 2012, 26:757-768. 10.1038/leu.2011.256, 21941364.
20. Ri M, Iida S, Nakashima T, Miyazaki H, Mori F, Ito A, Inagaki A, Kusumoto S, Ishida T, Komatsu H, Shiotsu Y, Ueda R. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia 2010, 24:1506-1512. 10.1038/leu.2010.137, 20555361.
21. de Wilt LH, Jansen G, Assaraf YG, van Meerloo J, Cloos J, Schimmer AD, Chan ET, Kirk CJ, Peters GJ, Kruyt FA. Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer. Biochem Pharmacol 2012, 83:207-217. 10.1016/j.bcp.2011.10.009, 22027222.
22. Groll M, Berkers CR, Ploegh HL, Ovaa H. Crystal structure of the boronic acidbased proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure 2006, 14:451-456. 10.1016/j.str.2005.11.019, 16531229.
23. Unno M, Mizushima T, Morimoto Y, Tomisugi Y, Tanaka K, Yasuoka N, Tsukihara T. The structure of the mammalian 20S proteasome at 2.75 A° resolution. Structure 2002, 10:609-618. 10.1016/S0969-2126(02)00748-7, 12015144.
24. Suzuki E, Demo S, Deu E, Keats J, Arastu-Kapur S, Bergsagel PL, Bennett MK, Kirk CJ. Molecular mechanisms of bortezomib resistant adenocarcinoma cells. PLoS One 2011, 6:e27996. 10.1371/journal.pone.0027996, 3245226, 22216088.
25. Wang L, Kumar S, Fridley BL, Kalari KR, Moon I, Pelleymounter LL, Hildebrandt MA, Batzler A, Eckloff BW, Wieben ED, Greipp PR. Proteasome beta subunit pharmacogenomics gene resequencing and functional genomics. Clin Cancer Res 2008, 14:3503-3513. 10.1158/1078-0432.CCR-07-5150, 2778274, 18519783.
26. Kale AJ, McGlinchey RP, Lechner A, Moore BS. Bacterial self-resistance to the natural proteasome inhibitor salinosporamide A. ACS Chem Biol 2011, 6:1257-1264. 10.1021/cb2002544, 3220761, 21882868.
27. Politou M, Karadimitris A, Terpos E, Kotsianidis I, Apperley JF, Rahemtulla A. No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to bortezomib. Leuk Res 2006, 30:240-241. 10.1016/j.leukres.2005.06.014, 16081156.
28. Lü S, Yang J, Huang C, Cheng H, Wang J. Up regulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen. Exp Hematol 2011, 39:1117-1118. 10.1016/j.exphem.2011.09.003, 21920470.
29. Lü S, Chen Z, Yang J, Chen L, Gong S, Zhou H, Guo L, Wang J. Overexpression of the PSMB5 Gene contributes to bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from Jurkat line. Exp Hematol 2008, 36:1278-1284. 10.1016/j.exphem.2008.04.013, 18562081.
30. Balsas P, Galán-Malo P, Marzo I, Naval J. Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy. Leuk Res 2012, 36:212-218. 10.1016/j.leukres.2011.09.011, 21978467.
31. Yang YM, Lee S, Nam CW, Ha JH, Jayaraman M, Dhanasekaran DN, Lee CH, Kwak MK, Kim SG. Ga12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 Downregulation. Carcinogenesis 2010, 31:1230-1237. 10.1093/carcin/bgq097, 20478922.
32. Kraus M, Rückrich T, Reich M, Gogel J, Beck A, Kammer W, Berkers CR, Burg D, Overkleeft H, Ovaa H, Driessen C. Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells. Leukemia 2007, 21:84-92. 10.1038/sj.leu.2404414, 17024115.
33. Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, Bahlis N, Belch A, Kunkel LA, Wear S, Wong AF, Wang M. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol 2012, 158:739-748. 10.1111/j.1365-2141.2012.09232.x, 22845873.
34. Xu GW, Ali M, Wood TE, Wong D, Maclean N, Wang X, Gronda M, Skrtic M, Li X, Hurren R, Mao X, Venkatesan M, Beheshti Zavareh R, Ketela T, Reed JC, Rose D, Moffat J, Batey RA, Dhe-Paganon S, Schimmer AD. The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. Blood 2010, 115:2251-2259. 10.1182/blood-2009-07-231191, 2920204, 20075161.
35. Chauhan D, Tian Z, Nicholson B, Kumar KG, Zhou B, Carrasco R, McDermott JL, Leach CA, Fulcinniti M, Kodrasov MP, Weinstock J, Kingsbury WD, Hideshima T, Shah PK, Minvielle S, Altun M, Kessler BM, Orlowski R, Richardson P, Munshi N, Anderson KC. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell 2012, 22:345-358. 10.1016/j.ccr.2012.08.007, 22975377.
36. Kale AJ, Moore BS. Molecular Mechanisms of Acquired Proteasome Inhibitor. Resistance. J Med Chem 2012, Epub ahead of print.
37. Shringarpure R, Catley L, Bhole D, Burger R, Podar K, Tai YT, Kessler B, Galardy P, Ploegh H, Tassone P, Hideshima T, Mitsiades C, Munshi NC, Chauhan D, Anderson KC. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br J Haematol 2006, 134:145-156. 10.1111/j.1365-2141.2006.06132.x, 16846475.
38. Chauhan D, Li G, Shringarpure R, Podar K, Ohtake Y, Hideshima T, Anderson KC. Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res 2003, 63:6174-6177.
39. McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 2008, 11:164-179. 10.1016/j.drup.2008.08.002, 18818117.
40. Zhou L, Hou J, Fu W, Wang D, Yuan Z, Jiang H. Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib. Leuk Res 2008, 32:1674-1683. 10.1016/j.leukres.2008.03.039, 18485479.
41. Siegel DS. Relapsed/Refractory multiple myeloma: defining refractory disease and identifying strategies to overcome resistance. Semin Hematol 2012, 49(Suppl 1):S3-S15.
42. Wang X, Li C, Ju S, Wang X, Li C, Ju S, Wang Y, Wang H, Zhong R. Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation. Leuk Lymphoma 2011, 52:1991-1998. 10.3109/10428194.2011.591004, 21718132.
43. Zang MR, Li F, An G, Xie ZQ, Li CH, Yu Z, Xu Y, Qiu LG, Hao M. Regulation of miRNA-15a/-16 expression on the drug resistance of myeloma cells. Zhonghua Yi Xue Za Zhi 2012, 92:1100-1103.
44. Chng WJ, Gualberto A, Fonseca R. IGF-1R is overexpressed in poor-prognostic subtypes of multiple myeloma. Leukemia 2006, 20:174-176. 10.1038/sj.leu.2403997, 16239907.
45. Tucci A, Bonadonna S, Cattaneo C, Ungari M, Giustina A, Guiseppe R. Transformation of a MGUS to overt multiple myeloma: the possible role of a pituitary macroadenoma secreting high levels of insulin-like growth factor 1 (IGF-1). Leuk Lymphoma 2003, 44:543-545. 10.1080/1042819021000037895, 12688330.
46. Bataille R, Robillard N, Avet-Loiseau H, Harousseau JL, Moreau P. CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity. Haematologica 2005, 90:706-707.
47. Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, Wei C, Baladandayuthapani V, Wang M, Thomas SK, Shah JJ, Weber DM, Orlowski RZ. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in pre-clinical models of multiple myeloma. Blood 2012, 120:3260-3270. 10.1182/blood-2011-10-386789, 22932796.
48. Que W, Chen J, Chuang M, Jiang D. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity. APMIS 2012, 120:195-203. 10.1111/j.1600-0463.2011.02836.x, 22339676.
49. Kim A, Park S, Lee JE, Jang WS, Lee SJ, Kang HJ, Lee SS. The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells. Leuk Res 2012, 36:912-920. 10.1016/j.leukres.2012.02.010, 22560334.
50. Yeom SY, Lee SJ, Kim WS, Park C. Rad knockdown induces mitochondrial apoptosis in bortezomib resistant leukemia and lymphoma cells. Leuk Res 2012, 36:1172-1178. 10.1016/j.leukres.2012.05.004, 22658652.
51. Gu JL, Li J, Zhou ZH, Liu JR, Huang BH, Zheng D, Su C. Differentiation induction enhances bortezomib efficacy and overcomes drug resistance in multiple myeloma. Biochem Biophys Res Commun 2012, 420:644-650. 10.1016/j.bbrc.2012.03.056, 22450313.
52. Jung HJ, Chen Z, Fayad L, Wang M, Romaguera J, Kwak LW, McCarty N. Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma. Exp Hematol 2012, 40:107-118.e2. 10.1016/j.exphem.2011.10.004, 3398482, 22024108.
53. Lü S, Chen Z, Yang J, Chen L, Zhou H, Xu X, Li J, Han F, Wang J. The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line 562/A02. Int J Lab Hematol 2010, 32:e123-e131. 10.1111/j.1751-553X.2009.01145.x, 19254348.
54. Verbrugge SE, Assaraf YG, Dijkmans BA, Scheffer GL, Al M, den Uyl D, Oerlemans R, Chan ET, Kirk CJ, Peters GJ, van der Heijden JW, de Gruijl TD, Scheper RJ, Jansen G. Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis. J Pharmacol Exp Ther 2012, 341:174-182. 10.1124/jpet.111.187542, 22235146.
55. Minderman H, Zhou Y, O'Loughlin KL, Baer MR. Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status. Cancer Chemother Pharmacol 2007, 60:245-255. 10.1007/s00280-006-0367-6, 17096161.
56. Rumpold H, Salvador C, Wolf AM, Tilg H, Gastl G, Wolf D. Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors. Biochem Biophys Res Commun 2007, 361:549-554. 10.1016/j.bbrc.2007.07.049, 17662692.